SPOTLIGHT: Novartis touts cancer data

Novartis has released positive data for RAD001 in advance of ASCO. According to interim data the therapy extended time without tumor growth from 1.9 months to 4 months and reduced the risk of progression by 70 percent. Release | Report

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.